Recent advances in the treatment of benign prostatic hyperplasia

被引:0
作者
Lai, MK
机构
关键词
benign prostatic hyperplasia; growth factors; testosterone; estrogen; p53; gene; apoptosis; transurethral resection of the prostate (TURP);
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The prevalence of benign prostatic hyperplasia (BPH) in Taiwanese men over the age of 50 years is as high as those in Western countries. BPH significantly affects the life quality of patients. Many theories of the genesis of BPH have been reported and some effective treatments have been designed according to these theories. Adequate preoperative studies can lead to satisfactory treatment results. Medical treatments including alpha-adrenergic blockers and 5-alpha-reductase inhibitors are frequently used as initial steps. Surgical treatment is necessary in more than one-quarter of patients in order to achieve good results. Transurethral resection of the prostate (TURF) remains the gold standard for treatment of BPH, although laser prostatectomy may become as popular as TURF in the future. Transurethral thermotherapy with microwave is also a promising new treatment. There are many other medical or surgical treatments under investigation. Further neuroendocrine research and studies with techniques of molecular biology may offer new concepts in BPH treatment in the future.
引用
收藏
页码:822 / 827
页数:6
相关论文
共 59 条
[1]  
[Anonymous], CHIN MED J
[2]   NATURAL-HISTORY OF BENIGN PROSTATIC HYPERPLASIA AND RISK OF PROSTATECTOMY - THE BALTIMORE LONGITUDINAL-STUDY OF AGING [J].
ARRIGHI, HM ;
METTER, EJ ;
GUESS, HA ;
FOZZARD, JL .
UROLOGY, 1991, 38 (01) :4-8
[3]   DNA-SYNTHESIS IN THE CANINE PROSTATE - EFFECTS OF ANDROGEN AND ESTROGEN-TREATMENT [J].
BARRACK, ER ;
BERRY, SJ .
PROSTATE, 1987, 10 (01) :45-56
[4]   USING REPEATED-MEASURES OF SYMPTOM SCORE, UROFLOWMETRY AND PROSTATE-SPECIFIC ANTIGEN IN THE CLINICAL MANAGEMENT OF PROSTATE DISEASE [J].
BARRY, MJ ;
GIRMAN, CJ ;
OLEARY, MP ;
WALKERCORKERY, ES ;
BINKOWITZ, BS ;
COCKETT, ATK ;
GUESS, HA ;
HOLTGREWE, HL ;
MCCONNELL, JD ;
SIHELNIK, SA ;
MCLEOD, M ;
WINFIELD, HN ;
WILLIAMS, R .
JOURNAL OF UROLOGY, 1995, 153 (01) :99-103
[5]   THE AMERICAN-UROLOGICAL-ASSOCIATION SYMPTOM INDEX FOR BENIGN PROSTATIC HYPERPLASIA [J].
BARRY, MJ ;
FOWLER, FJ ;
OLEARY, MP ;
BRUSKEWITZ, RC ;
HOLTGREWE, HL ;
MEBUST, WK ;
COCKETT, ATK ;
BLAIVAS, JG ;
WEIN, AJ .
JOURNAL OF UROLOGY, 1992, 148 (05) :1549-1557
[6]  
BARRY MJ, 1990, UROL CLIN N AM, V17, P495
[7]   CELL-PROLIFERATION, DNA-REPAIR, AND P53 FUNCTION ARE NOT REQUIRED FOR PROGRAMMED DEATH OF PROSTATIC GLANDULAR CELLS INDUCED BY ANDROGEN ABLATION [J].
BERGES, RR ;
FURUYA, Y ;
REMINGTON, L ;
ENGLISH, HF ;
JACKS, T ;
ISAACS, JT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (19) :8910-8914
[8]   HIGH-INTENSITY FOCUSED ULTRASOUND FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA - EARLY UNITED-STATES CLINICAL-EXPERIENCE [J].
BIHRLE, R ;
FOSTER, RS ;
SANGHVI, NT ;
DONOHUE, JP ;
HOOD, PJ .
JOURNAL OF UROLOGY, 1994, 151 (05) :1271-1275
[9]   MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA BY TRANSURETHRAL LASER-ABLATION IN PATIENTS TREATED WITH WARFARIN ANTICOAGULATION [J].
BOLTON, DM ;
COSTELLO, AJ .
JOURNAL OF UROLOGY, 1994, 151 (01) :79-81
[10]  
Boyarsky S, 1976, Trans Am Assoc Genitourin Surg, V68, P29